Table 10.
Cervical and Thoracic Injuries: Liver Enzyme and Bilirubin Elevations at Admission and during Riluzole Administrationa
| ALT N (%) | AST N (%) | ALP N (%) | GGT N (%) | Bilirubin N (%) | |
|---|---|---|---|---|---|
| Admission before riluzole | |||||
| Normal | 27 (87) | 20 (62) | 32 (100) | 25 (89) | 29 (91) |
| Mildb | 3 (10) | 8 (25) | 0 (0) | 3 (11) | 3 (9) |
| Moderatec | 1 (3) | 4 (12) | 0 (0) | 0 (0) | 0 (0) |
| Severed | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Total | 31 (100) | 32 (100) | 32 (100) | 28 (100) | 32 (100) |
| While receiving riluzole | |||||
| Normal | 10 (28) | 12 (33) | 30 (83) | 15 (44) | 31 (86) |
| Mildb | 15 (42) | 16 (44) | 5 (14) | 13 (38) | 4 (11) |
| Moderatec | 10 (28) | 7 (19) | 1 (3) | 5 (15) | 1 (3) |
| Severed | 1 (3) | 1 (3) | 0 (0) | 1 (3) | 0 (0) |
| Total | 36 (100) | 36 (100) | 36 (100) | 34 (100) | 36 (100) |
a
See Figure 2.
b
Mild: >ULN to 2.5×ULN.
c
Moderate: >2.5–5×ULN.
d
Severe: >5–20×ULN.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; ULN, upper limit of normal.